Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.70 |
| ▸ | CYP11B1 | P15538 | 6/20 | 0.61 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.61 |
| ▸ | TNF | P01375 | 1/20 | 0.61 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.56 |
| ▸ | FDPS | P14324 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | APAF1 | O14727 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30038122 | 1.00 | TDP1 (0.70) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL230376 | 0.84 | TDP1 (0.78) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL6794361 | 0.83 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL6442808 | 0.83 | TDP1 (1.00) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL30564238 | 0.83 | TDP1 (0.76) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL32660136 | 0.82 | TDP1 (0.74) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL3065318 | 0.82 | TDP1 (0.74) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL3079522 | 0.82 | TDP1 (0.68) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL825505 | 0.81 | TDP1 (0.72) | TDP1CYP11B1CYP11B2TNFEGLN3 | |
| SCHEMBL3966477 | 0.81 | TDP1 (0.73) | TDP1CYP11B1CYP11B2TNFEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 136 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112724757-A | Ionomer coating for eliminating surface charge, preparation method thereof and corresponding coating | 徐宁 | 2021-04-30 | — | — | CN | claimed |
| CN-110904473-A | 5G antenna environment-friendly copper plating process | 中山美力特环保科技有限公司 | 2020-03-24 | — | — | CN | claimed |
| CN-105367862-A | Car sealing strip material TPV and preparation method thereof | ANHUI XIONGYA PLASTIC TECH CO LTD | 2016-03-02 | — | — | CN | claimed |
| US-5548003-A | ADDUCT DISPERSED IN WATER-BASED PRINTING INK | ARMSTRONG WORLD INDUSTRIES, INC. (US) | 1996-08-20 | — | — | US | claimed |
| CN-122011867-A | Ionomer coatings for eliminating surface charge, method for preparing same and corresponding coatings | 徐宁 | 2026-05-12 | — | — | CN | disclosed |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | DOW TECHNOLOGY INVESTMENTS LLC (US) | 2024-05-30 | — | — | US | disclosed |
| EP-4347544-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | Dow Technology Investments LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117242047-A | Process for the vapor phase hydrogenation of aldehydes | 陶氏技术投资有限责任公司 | 2023-12-15 | — | — | CN | disclosed |
| CN-110156708-B | Substituted heterocyclic compound containing acylhydrazone skeleton and preparation method and application thereof | 中国药科大学 | 2022-08-09 | — | — | CN | disclosed |
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FORMA THERAPEUTICS, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FORMA THERAPEUTICS, INC. (US) | 2021-05-04 | — | — | US | disclosed |
| CN-112724757-A | Ionomer coating for eliminating surface charge, preparation method thereof and corresponding coating | 徐宁 | 2021-04-30 | — | — | CN | disclosed |
| US-4492708-A | Antiviral benzimidazoles | ELI LILLY AND COMPANY (US) | 1985-01-08 | — | — | US | disclosed |
| EP-0111993-A2 | Improvements in or relating to benzimidazoles | ELI LILLY AND COMPANY (US) | 1984-06-27 | — | — | EP | disclosed |
| US-4424362-A | Process for preparing a trans-6-propenyl benzimidazole | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4424362-A | Process for preparing a trans-6-propenyl benzimidazole | ELI LILLY AND COMPANY (US) | 1984-01-03 | — | — | US | disclosed |
| US-4420479-A | 1-SUBSTITUTED, 2-AMINO-BENZIMIDAZOLES | ELI LILLY AND COMPANY (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0091795-A1 | Olefinic benzimidazoles | ELI LILLY AND COMPANY (US) | 1983-10-19 | — | — | EP | disclosed |
| US-4243806-A | ANTIALLERGENS; ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1981-01-06 | — | — | US | disclosed |
| US-4179505-A | ANTIALLERGENS; ANTIHISTAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210214323-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN | FASN, FABP1, SCD | TDP1 3567/4885CYP11B1 219/4885CYP11B2 276/4885 |
| US-10995078-B2 | Compounds and compositions for inhibition of FASN | FASN, FABP1, SCD | TDP1 3712/4885CYP11B1 189/4885CYP11B2 248/4885 |
| US-20240174583-A1 | PROCESSES FOR THE VAPOR PHASE HYDROGENATION OF ALDEHYDES | ADH1C, ADH5, ALDH2 | TDP1 1008/4885CYP11B1 1855/4885CYP11B2 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.